ITRM (Iterum Therapeutics) EV-to-EBIT : -3.07 (As of Jun. 26, 2025)

Iterum Therapeutics EV-to-EBIT Chart

Iterum Therapeutics Annual Data
	Trend	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-EBIT		Get a 7-Day Free Trial				-2.06	-0.20	0.52	-0.60	-3.51

Iterum Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															-0.82	-1.09	-1.16	-3.51	-3.20

Competitive Comparison of Iterum Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Iterum Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iterum Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's EV-to-EBIT falls into.

Iterum Therapeutics EV-to-EBIT Calculation

Iterum Therapeutics's EV-to-EBIT for today is calculated as:

Iterum Therapeutics's current Enterprise Value is $60.57 Mil.
Iterum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics  (NAS:ITRM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Iterum Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Iterum Therapeutics's Enterprise Value for the quarter that ended in Mar. 2025 was $63.27 Mil.
Iterum Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Iterum Therapeutics Business Description